Research Highlight |
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Research Highlight |
Twice-yearly inclisiran injections halve LDL-cholesterol levels
The safety and durability of the LDL-cholesterol-lowering effects of inclisiran, a small interfering RNA that inhibits the synthesis of PCSK9 in the liver, have now been confirmed in three phase III clinical trials published in the New England Journal of Medicine.
A hydrogel–miRNA complex stimulates heart recovery
Antisense inhibitor of apo B has potent lipoprotein effects